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Over the last 50 years, the list of doping 
substances and methods has been progres-
sively expanding, being regularly reviewed 
by the international antidoping authorities 
(formerly the Medical Commission of the 
International Olympic Committee, and after-
ward, following its constitution in 1999, the 
World Anti-Doping Agency [WADA]). New 
substances/classes of substances have been 
periodically included in the list, keeping the 
pace with more advanced and sophisticated 
doping trends. At present, and apart from 
the prohibited performance enhancing and 
masking methods (e.g., blood transfusions 
and tampering strategies), the list comprises 
several hundreds of biologically active sub-
stances, with broad differences in their physi-
cochemical properties (i.e., molecular weight, 
polarity and acid-basic properties) [1]. As a 
consequence, the ‘one class – one procedure’ 
approach, which had been followed by nearly 
all accredited antidoping laboratories world-
wide until the turn of the millennium, is no 
longer sustainable. The need to minimize the 
overall number of independent analytical pro-
cedures, and, in parallel, to reduce the analyti-
cal costs, stimulated the development of multi-
targeted methods, aimed to increase the overall 
ratio of ‘target analytes: procedure’ [2–6].
The above evolution has not always been 
a straight forward process. The need to com-
ply with the WADA technical requirements 
(both in terms of identification criteria and of 
minimum required performance limits [7,8]) 
and with the reduction of the reporting time 
(a constraint that becomes even more criti-
cal during international sport events, where 
the daily workload also drastically increases) 
has imposed a thorough re-planning of the 
analytical procedures.
The development of an antidoping analyti-
cal method requires the appropriate knowl-
edge not only of the biophysicochemical 
properties of the target analyte, but also of its 
PK profile. Historically, immunological meth-
ods and GC-based techniques were applied 
in antidoping science, as preferential screen-
ing methods for the detection of prohibited 
substances, which were originally limited to 
nonendogenous stimulants and narcotics. In 
the 1980s, GC–MS became the reference ana-
lytical platform for the detection and quanti-
fication of the majority of the low molecular 
weight doping substances [3–6]. In the follow-
ing two decades, with the inclusion in the 
Prohibited List of new classes of low molecular 
weight, hydrophilic, thermolabile, nonvolatile 
analytes (including, but not limited to, gluco-
corticoids and designer steroids) and simulta-
neously of peptide hormones, scientists were 
obliged to design, develop, validate and apply 
techniques based on LC–MS/MS.
From single-class to multiclass 
approaches
Analysis of small molecules
As mentioned above, LC–ESI-MS(/MS)-
based methods were initially developed to 
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target those categories of prohibited drugs that would 
have been undetectable (e.g., peptide hormones) or 
barely detectable (e.g., glucocorticoids) with conven-
tional GC-MS-based techniques, as well as for com-
pounds that (although detectable by GC–MS) required 
extensive, time-consuming sample- preparation proce-
dures (e.g., diuretics). The progressive advancement 
of the technical performance of bench-top mass spec-
trometers, in terms of ionization sources, scan speed 
and polarity switching capability, paralleled by a simi-
lar improvement of the chromatographic separation 
techniques, in terms of chromatographic hardware, 
stationary phases (e.g., hydrophilic interaction chro-
matography) and packing material characteristics and 
sizes (e.g., fused-core, monolithic, sub-2 μm), allowed 
the development of rapid and effective multitargeted 
screening procedures, permitting to simplify the 
sample preparation procedure, while at the same time 
reducing the volume of biological sample required for 
the assay, and the overall cost and time of operation 
per sample. A peculiar feature of the newly developed 
LC–MS(/MS)-based procedures was the possibility to 
screen for a considerable number of markedly differ-
ent analytes/classes of analytes in a single chromato-
graphic run, initially using HPLC interfaced with 
low-resolution mass spectrometers and, more recently, 
coupling UHPLC technology with either low- or 
high-resolution mass spectrometers [9–13].
Analysis of macromolecules
The inclusion in the Prohibited List of peptide hor-
mones with low molecular weight (<2000 Da) and 
with minimal differences in the aminoacidic sequence 
with respect to those produced endogenously has 
imposed the development of analytical strategies based 
on mass spectrometric identification. Different proce-
dures were initially developed to detect insulin and its 
analogs, the corticotrophin synacthen (ACTH 1–24), 
the luteinizing hormone releasing hormone (LH-RH, 
gonadorelin), desmopressin and its analogs, and the 
entire class of GHRPs using low-resolution mass spec-
trometers and μLC techniques. Nano-LC coupled 
with high-resolution mass spectrometers was then pre-
ferred, due to sensitivity and selectivity issues [4,9,14]. 
Recently, multianalyte screening procedures have also 
been developed to detect small peptides by means of 
mixed-mode weak cation exchange SPE followed by 
LC–ESI-MS-based techniques [15–17]; while peptide 
hormones with medium-molecular weight (e.g., insu-
lins, tesamorelin, sermorelin, CJC-1293, CJC-1295, 
synacthen and IGF1 analogs) were proposed to be 
screened for by methods based on immunoaffinity 
purification followed by LC–ESI-MS/MS [18].
From targeted to ‘omic’ approaches
Analytical procedures based on targeted approaches are 
very specific and sensitive, however, their application is 
limited to preselected groups of compounds, previously 
characterized in sufficient details both in terms of their 
PK properties and chromatographic-spectrometric 
profile. To also detect potentially unknown targets, 
high-resolution mass spectrometers operating in full-
scan mode can be used for the detection of a virtually 
unlimited range of known and unknown substances. 
TOF- and Orbitrap-based technologies are currently 
the most common high-resolution mass analyzers used 
in doping control analysis. The main advantage of 
these instrumental platforms is their capability of col-
lecting data at very fast scan rates, which also allows 
the retrospective interpretation of the results originally 
obtained on the samples (including those that may 
have originally been reported as negative), to verify the 
possible presence of prohibited substances that were 
unknown at the time of the original analysis. This is 
possible by reprocessing the data files without the need 
of reanalyzing the samples [3–6]. This feature is par-
ticularly useful not only to detect new designer drugs, 
but also to increase the detectability of several prohib-
ited agents and to ensure the detection of new doping 
practices. The possibility of monitoring a huge amount 
of data opens the way to ‘omic’ approaches, where the 
alteration of specific biomarkers/biomarker profiles 
might be used as proof of a doping offense.
Conclusion: what is next?
From the early days of sports drug testing, the ‘doping 
community’ has continuously moved toward strategies 
capable of increasing athletic performance, always with 
the parallel objective of circumventing existing antidop-
ing regulations, testing strategies and laboratory meth-
ods. Doping analysis has always been a race against 
time. A race that is usually intended as the need, for 
the scientists of the antidoping community to quickly 
identify emerging substances of abuse and practices 
employed by athletes to improve performance, and to 
immediately update, improve and expand the existing 
panel of analytical methods. LC–MS has been one of 
the most effective tools in this race.
The combination of direct and indirect methods, as 
well as the combination of mass spectrometric-based 
techniques with molecular and cellular biology meth-
odologies, seems to be the most promising detection 
“The development of an antidoping 
analytical method requires the 
appropriate knowledge not only of the 
biophysicochemical properties of the target 
analyte, but also of its PK profile.”
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strategy to ensure the most complete coverage of doping 
substances and methods, narrowing the gap between the 
number of athletes who dope and the number of ath-
letes who are caught [19,20]. In this scenario, either mul-
titargeted (carried out on specific analytes or selected 
biomarkers) or untargeted methods based on LC–MS, 
represent the prevalent analytical tool to keep the pace 
with the constantly evolving doping trends. Nonetheless, 
although highly effective, rapid and sensitive, the mul-
tianalyte procedure find their most appropriate use as 
screening analyses (also defined ‘initial testing analysis’, 
e.g., by the WADA). Although modern LC–MS/MS sys-
tems ensure remarkable selectivity, in terms of chromato-
graphic separation and mass spectrometric identification, 
the risk of potential interferences still exists, particularly 
from nonprohibited substances and/or their metabolites, 
which may also be present in the tested biological sample, 
and that are generally not considered when a new method 
is validated. To ensure the unambiguous identification 
(and where so required by the WADA rules, the quan-
titative determination) of all relevant analytes, the ideal 
analytical strategy should always be based on the com-
bination of: multianalyte, highly sensitive, initial testing 
(‘screening’) procedures (no false-negative results, with 
the occurrence of false-positive kept to a minimum); and 
highly sensitive and, crucially, highly selective confirma-
tion procedures, allowing virtual annulment of the risk 
of false-positive results.
As previously mentioned, the development of effec-
tive laboratory methods requires the knowledge of 
physicochemical properties, and of the PK profile of 
a doping substance. Information on metabolism and 
excretion kinetics of doping substances should also 
always be taken into account when a doping test ses-
sion is planned. As no laboratory method, as effec-
tive as it can be, can counter balance the uselessness 
of an ill-timed test. In this scenario, modulation of 
the PK profile – either by the use of drug-delivery 
systems, to incorporate and transport the prohibited 
substances, and/or the co-administration of a doping 
substance with nonprohibited drug, to take advantage 
of drug–drug interactions altering the metabolism of 
the former – may be the next strategy to challenge 
the efficacy of laboratory methods. But WADA- 
accredited laboratories are already reacting, and the 
race continues.
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